المنشورات طباعة Velez MG, Kosiorek HE, Egan JB, McNatty AL, Riaz IB, Hwang SR, Stewart GA, Ho TH, Moore CN, Singh P, Sharpsten RK, Costello BA, Bryce AH. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2022 Sep; 25 (3):479-483 Epub 2021 July 22 View PubMed Liu AJ, Kosiorek HE, Ueberroth BE, Jaeger E, Ledet E, Kendi AT, Tzou K, Quevedo F, Choo R, Moore CN, Ho TH, Singh P, Keole SR, Wong WW, Sartor O, Bryce AH. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases. Prostate. 2022 Sep; 82(12):1202-1209. Epub 2022 Jun 02. View PubMed Nafissi NN, Kosiorek HE, Butterfield RJ, Moore C, Ho T, Singh P, Bryce AH. Evolving Natural History of Metastatic Prostate Cancer. Cureus. 2020 Nov 14; 12 (11):e11484 View PubMed Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S, Petros W, Yenser S, Gockerman JP, Sleep D, Hurwitz H, George DJ. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2008 Oct 1; 14 (19):6270-6 View PubMed Moore CN, George DJ. Update in the management of patients with hormone-refractory prostate cancer. Curr Opin Urol. 2005 May; 15 (3):157-62 View PubMed PST-20466917 الصفحة الرئيسية المنشورات